NICE updates guidance on fever in young children

NICE updates guidance on fever in young children

August 14 2017 A number of changes have been made to the NICE guidelines and assessing and...

National measles guidelines published

National measles guidelines published

August 14 2017 Updated guidelines relating to measles identification, case management and control...

Wales recommits to supporting those affected by neurological conditions

Wales recommits to supporting those affected by neurological conditions

August 1 2017The Welsh Government has renewed its commitment to supporting people with...

Study indicates 11.8m people should be on statins

Study indicates 11.8m people should be on statins

August 3 2017 Millions of people are not being prescribed a statin despite NICE guidelines...

EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

June 29 2016 Adempas (riociguat) should not be used in patients with symptomatic pulmonary...

  • NICE updates guidance on fever in young children

    NICE updates guidance on fever in young children

    Monday, 14 August 2017 09:59
  • National measles guidelines published

    National measles guidelines published

    Monday, 14 August 2017 09:16
  • Wales recommits to supporting those affected by neurological conditions

    Wales recommits to supporting those affected by neurological conditions

    Saturday, 05 August 2017 13:54
  • Study indicates 11.8m people should be on statins

    Study indicates 11.8m people should be on statins

    Saturday, 05 August 2017 14:51
  • EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

    EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

    Wednesday, 29 June 2016 10:44

drugalertJune 29 2016

Adempas (riociguat) should not be used in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonia or PH-IIP, the European Medicines Agency has warned.

Although the drug is not authorised for use in PH-IIP patients, the EMA has issued the recommendation following the early termination of a phase II clinical trial, RISE-IIP, investigating the effects of Adempas in this patient population.

“Preliminary results showed an increased number of deaths and serious adverse events, including breathing problems and lung infections, with Adempas compared with placebo. The available data do not indicate a clinically significant benefit from Adempas treatment in these patients,” said the EMA’s announcement, published on June 24.

The trial had been assessing the medicine in 145 PH-IIP patients, with the primary endpoint being the change in the 6-minute walking distance test after 6 months of treatment. “At the time of the interim assessment leading to the termination of the trial, 21 deaths had been observed, 17 patients taking Adempas and 4 patients taking placebo. Serious adverse events, which were mostly respiratory disease or lung infections, were also higher among patients taking Adempas.”

EMA is advising health professionals that “if any patients with PH-IIP are being treated with Adempas, this treatment should be discontinued and the patient’s clinical status carefully monitored.” A contraindication will also be included in prescribing information, and EMA will be issuing a letter to health professionals. 

It has also stated that Adempas continues to have a positive benefit-risk balance for its authorised uses.

The product’s indications in the UK are:

  • treating adults with WHO Functional Class (FC) II to III with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity
  • as monotherapy or in combination with endothelin receptor antagonists for adults with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.

Links:

EMA announcement

Adempas SPC on eMC

Clinical News

August 18 2017 GPs lack familiarity with current physical activity guidelines, a survey has found. Only 20% of the 1,013 GPs in England responding to the survey “were broadly or very familiar with the...
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...